Merck KGaA (MRK.DE) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. MRK.DE files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.05% | 30.00% | Pass |
| Interest-bearing investments | 4.89% | 30.00% | Pass |
| Non-permissible income | 0.44% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 24.45% | 33.00% | Pass |
| Interest-bearing investments | 5.68% | 33.00% | Pass |
| Non-liquid assets | 86.66% | at least 20.00% | Pass |
| Non-permissible income | 0.44% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 24.45% | 33.33% | Pass |
| Cash + interest-bearing securities | 5.68% | 33.33% | Pass |
| Accounts receivable | 13.34% | 33.33% | Pass |
| Non-permissible income | 0.44% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 24.45% | 33.33% | Pass |
| Cash + interest-bearing securities | 5.68% | 33.33% | Pass |
| Accounts receivable | 13.34% | 50.00% | Pass |
| Non-permissible income | 0.44% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 22.42% | 33.00% | Pass |
| Cash + interest-bearing securities | 5.21% | 33.00% | Pass |
| Accounts receivable | 7.02% | 33.00% | Pass |
| Non-permissible income | 0.44% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.05% | 33.00% | Pass |
| Cash + interest-bearing securities | 4.89% | 49.00% | Pass |
| Accounts receivable | 6.59% | 49.00% | Pass |
| Non-permissible income | 0.44% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.05% | 33.33% | Pass |
| Cash + interest-bearing securities | 4.89% | 33.33% | Pass |
| Accounts receivable | 11.48% | 49.00% | Pass |
| Non-permissible income | 0.44% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 31.50 | NEUTRAL |
| Stochastic %K (14) | 16.02 | BUY |
| CCI (20) | -235.53 | BUY |
| Williams %R (14) | -83.98 | BUY |
| MACD (12,26,9) | -0.61 | SELL |
| ROC (10) | -4.77 | SELL |
| Momentum (10) | -6.65 | SELL |
| EMA (10) | 136.90 | SELL |
| SMA (10) | 137.88 | SELL |
| EMA (20) | 138.10 | SELL |
| SMA (20) | 137.99 | SELL |
| EMA (30) | 138.52 | SELL |
| SMA (30) | 139.90 | SELL |
| EMA (50) | 137.89 | SELL |
| SMA (50) | 140.04 | SELL |
| EMA (100) | 133.67 | SELL |
| SMA (100) | 133.10 | SELL |
| EMA (200) | 126.49 | BUY |
| SMA (200) | 124.97 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
